Abstract
Chemotherapy does not increase the survival time of patients treated for rectal cancer. Chemotherapy given concomitantly to radiotherapy and combined before or after radiation significantly reduces the risk of local recurrence. The sterilization of the tumour (complete pathological response) by chemotherapy is a favourable prognostic factor. New trials on optimisation of pathological complete response rates are based on using drugs effective on metastatic colorectal cancer, given prior to chemoradiotherapy and followed by a resection at least 8 weeks after the end of the radiotherapy. The level of evidence for postoperative chemotherapy is low due to lack of specific study. The indication of postoperative chemotherapy depends on the disease extent after preoperative treatment.
Copyright © 2011 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / radiotherapy
-
Adenocarcinoma / surgery
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Capecitabine
-
Cetuximab
-
Chemotherapy, Adjuvant
-
Clinical Trials as Topic / statistics & numerical data
-
Combined Modality Therapy
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Disease-Free Survival
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Fluorouracil / therapeutic use
-
Humans
-
Irinotecan
-
Neoadjuvant Therapy
-
Neoplasm Recurrence, Local / prevention & control
-
Organoplatinum Compounds / administration & dosage
-
Oxaliplatin
-
Radiotherapy, Adjuvant
-
Rectal Neoplasms / drug therapy*
-
Rectal Neoplasms / radiotherapy
-
Rectal Neoplasms / surgery
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antimetabolites, Antineoplastic
-
Organoplatinum Compounds
-
Oxaliplatin
-
Deoxycytidine
-
Capecitabine
-
Irinotecan
-
Cetuximab
-
Fluorouracil
-
Camptothecin